EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Super‐Enhancer‐Driven Transcriptional Regulatory Circuit Underlying Abiraterone Resistance in Castration‐Resistant Prostate Cancer

Liling Jiang, Jiamin Wang, Guanjie Peng, Haichuan Zhang, Jinxin Fang, Yingyin Gao, Enzhe Lou, Yangzhou Liu, Wa Ding, Bingyuan Liu, Qiong Mao, Lizhen Jiang und 7 weitere

Advanced Science · 2025

DOI: 10.1002/advs.202501284 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Liling Jiang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, Sino-French Hoffmann Institute, School of Basic …. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Androstenes, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, Guangzhou Science, Technology and Innovation Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Castration‐resistant prostate cancer (CRPC) remains the leading cause of mortality among prostate cancer patients. While second‐generation androgen receptor (AR) pathway‐targeted therapies, such as Abiraterone, have significantly improved survival outcomes, resistance to these treatments ultimately emerges, posing a critical challenge. Understanding the mechanisms underlying Abiraterone resistance is essential for developing strategies to enhance patient outcomes. In this study, a super‐enhancer (SE)‐driven transcriptional regulatory circuit is identified involving BCL6, NFIB, and SMAD3 that facilitates Abiraterone resistance in CRPC. Through comprehensive analyses of SE expression profiles in Abiraterone‐resistant CRPC cells and their parental counterparts, it is revealed that this circuit plays a pivotal role in resistance progression. Mechanistically, BCL6, NFIB, and SMAD3 synergistically remodel the transcriptional landscape of resistant CRPC cells, driving resistance by regulating cholesterol biosynthesis and cell cycle pathways. The findings provide critical insights into the transcriptional dysregulation underlying Abiraterone resistance and highlight potential therapeutic strategies to counteract treatment resistance in CRPC, ultimately aiming to improve patient survival and quality of life.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantAndrostenesDrug Resistance, NeoplasmMaleHumansGene Expression Regulation, NeoplasticCell Line, TumorGene Regulatory Networks

Stichwörter der Autor:innen

abiraterone resistancecastration‐resistant prostate cancertranscriptional regulation

Substanzen

abirateroneAndrostenes

Autor:innen und Institutionen

  • Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, Sino-French Hoffmann Institute, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, Guangdong,…
  • The Affiliated Traditional Chinese Medicine Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510130, P. R. China.
  • Department of Urology, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, The Third Affiliated Hospital, Guangzhou Medical Unive…
  • Clinical Big Data Research Center, Scientific Research Center, The Seventh Afffliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, 518107, P. R. China.
  • Department of Urology, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510120, P. R. China.

ORCID-Profile: Xianping Shi

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangdong Province
  • Guangzhou Science, Technology and Innovation Commission
  • Shenzhen Medical Research Fund

Zitieren

APA

Jiang, L., Wang, J., Peng, G., Zhang, H., Fang, J., Gao, Y., Lou, E., Liu, Y., Ding, W., Liu, B., Mao, Q., Jiang, L., Liu, A., Li, X., Hu, S., Ma, Q., Zheng, Y., Zhao, Z., & Shi, X. (2025). A Super‐Enhancer‐Driven Transcriptional Regulatory Circuit Underlying Abiraterone Resistance in Castration‐Resistant Prostate Cancer. Advanced Science. https://doi.org/10.1002/advs.202501284

Vancouver

Jiang L, Wang J, Peng G, Zhang H, Fang J, Gao Y, et al. A Super‐Enhancer‐Driven Transcriptional Regulatory Circuit Underlying Abiraterone Resistance in Castration‐Resistant Prostate Cancer. Advanced Science. 2025. doi:10.1002/advs.202501284

BibTeX
@article{Jiang2025,
  author = {Jiang, Liling and Wang, Jiamin and Peng, Guanjie and Zhang, Haichuan and Fang, Jinxin and Gao, Yingyin and Lou, Enzhe and Liu, Yangzhou and Ding, Wa and Liu, Bingyuan and Mao, Qiong and Jiang, Lizhen and Liu, Aochu and Li, Xinyue and Hu, Shiwen and Ma, Qiaomin and Zheng, Yueyuan and Zhao, Zhigang and Shi, Xianping},
  title = {A Super‐Enhancer‐Driven Transcriptional Regulatory Circuit Underlying Abiraterone Resistance in Castration‐Resistant Prostate Cancer},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202501284}
}
Kostenlos starten →